Dianthus Therapeutics (DNTH) Accounts Payables (2017 - 2025)

Dianthus Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $9.7 million for Q4 2025.

• On a quarterly basis, Accounts Payables rose 112.38% year-over-year to $9.7 million in Q4 2025; TTM through Dec 2025 was $9.7 million, a 112.38% increase from a year earlier, with the FY2025 full-year figure at $9.7 million, up 112.38% from the prior year.
• Accounts Payables advanced to $9.7 million in Q4 2025 per DNTH's latest filing, from $6.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $9.7 million in Q4 2025 and bottomed at $813000.0 in Q2 2023.
• The 5-year median for Accounts Payables is $2.8 million (2021), against an average of $3.7 million.
• Across the five-year window, Accounts Payables sank 75.66% in 2023 and jumped 453.1% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $3.0 million in 2021, then sank by 61.61% to $1.2 million in 2022, then soared by 123.65% to $2.6 million in 2023, then jumped by 75.44% to $4.6 million in 2024, then surged by 112.38% to $9.7 million in 2025.
• Per Business Quant, the three latest DNTH Accounts Payables figures stand at $9.7 million (Q4 2025), $6.7 million (Q3 2025), and $5.4 million (Q2 2025).